EPISODE · Mar 11, 2026 · 2 MIN
Fremanezumab Reduces Prolonged Sporadic Hemiplegic Migraine Rate
from TheBrief.Health · host TheBrief.Health
Fremanezumab, a CGRP-targeting preventive therapy, may reduce prolonged sporadic hemiplegic migraine attacks, offering a promising option for patients with stroke-like symptoms and limited disease-specific treatments.
What this episode covers
Fremanezumab, a CGRP-targeting preventive therapy, may reduce prolonged sporadic hemiplegic migraine attacks, offering a promising option for patients with stroke-like symptoms and limited disease-specific treatments.
NOW PLAYING
Fremanezumab Reduces Prolonged Sporadic Hemiplegic Migraine Rate
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m